Articles tagged with Insulin
Researchers discovered that insulin signaling converges with nutrient metabolism pathways to regulate lipid synthesis in the liver. The study suggests that multiple pathways are required for insulin-resistant livers to accumulate lipids.
Scientists at Stanford University have identified a molecular pathway responsible for the decline of beta cell division with age. By manipulating this pathway, they can restore the ability of older beta cells to divide and generate new cells, potentially leading to breakthroughs in treating both type 1 and type 2 diabetes.
Researchers at Stanford University School of Medicine have identified a key molecular pathway responsible for the decrease in insulin-producing cells with age. Activating this pathway may lead to a new treatment for diabetes, and recent studies have shown promising results in mice.
A team of researchers has identified Sirt1 as a crucial protein linking caloric restriction to improved insulin action in skeletal muscle. This finding provides new targets for therapeutics to reduce insulin resistance and lower the risk of developing type 2 diabetes.
A study has identified a gene, Tomosyn-2, that confers diabetes susceptibility in obese mice by regulating insulin secretion. The protein acts as a brake on insulin release from the pancreas, and its destabilization allows for sufficient insulin production to prevent diabetes.
A study published in PLOS Genetics identified a gene and protein involved in regulating insulin secretion in obese mice. The researchers found that a single amino acid difference in the tomosyn-2 protein destabilizes it, leading to an insufficient insulin response and diabetes susceptibility.
Scientists at Cold Spring Harbor Laboratory have identified a new approach to treating diabetes and obesity by targeting the PTP1B enzyme, which is crucial in regulating insulin signaling. By oxidizing a specific cysteine residue, the enzyme's activity is temporarily halted, allowing for improved insulin sensitivity.
Patients with uncontrolled diabetes saw faster blood glucose, blood pressure, and cholesterol level control with more frequent primary care visits every two weeks. The study found that doubling the time between physician encounters increased median times to reach treatment targets by 35-87%.
Researchers at Salk Institute have discovered how a hormone turns on molecular switches inside the pancreas, increasing insulin production. The finding raises the possibility of new designer drugs to help Americans with type 2 diabetes or pre-diabetic insulin resistance.
The NHS has wasted £625 million on synthetic insulin over the past decade, as recommended human alternatives would have been just as effective, reveals research published in BMJ Open. The study analyzed publicly available data and found that the annual cost of synthetic insulin rose from 12% to 85% of total costs.
A randomized controlled trial found that intranasal insulin therapy improved delayed story recall and preserved general cognition in adults with mild cognitive impairment or Alzheimer's disease. The treatment also stabilized cerebral glucose metabolism and functional abilities in older adults.
Scientists at UCSF discover that fetal tissue, called mesenchyme, secretes chemicals essential for mature beta cell formation. This breakthrough may lead to new ways of addressing Type 1 and Type 2 diabetes, including generating fully functional beta cells from stem cells or increasing beta cell numbers in people with Type 2 diabetes.
A study by Sanford Burnham Prebys reveals that CDP138 is a crucial protein for insulin-stimulated glucose uptake in muscle and fat cells. The researchers found that optimal insulin response requires the correct insertion of GLUT4 into the cellular membrane, with CDP138 playing a key role.
Recent concerns about airplane travel and insulin pump delivery may be overstated due to limited data, according to an editorial. The effects of changes in atmospheric pressure on insulin delivery remain unclear, and more research is needed before drawing conclusions.
Scientists identify uroguanylin as a potential target for controlling appetite and obesity. They also found a link between Parkinson disease and fat levels in the blood, with implications for treating this neurodegenerative disorder.
A team of researchers has discovered that a genetic mutation in the CDKAL1 gene can lead to misreading of specific parts of the insulin-producing gene, resulting in decreased insulin production and impaired cell function. This finding sheds light on the underlying mechanisms of Type 2 diabetes.
Researchers at Helmholtz-Zentrum Dresden-Rossendorf develop a system to recreate amyloid formation on artificial surfaces, providing insights into disease mechanisms. The customized mica surface exhibits hydrophobic properties, facilitating the formation of oligomers and fibrils that can destroy cell surfaces.
Researchers at Penn State have discovered that particles in liquids don't always settle at the bottom based on size or speed. Instead, they arrange themselves in a way that achieves the lowest energy state, often resulting in a layered structure with larger particles at the bottom and smaller ones above.
A post-hoc analysis shows that JANUMET (sitagliptin/metformin) achieved better A1C goal attainment compared to metformin alone, particularly in patients with baseline A1C between 7.5 and 9.0 percent. The study found that nearly half of these patients achieved the target A1C level after 18 weeks on JANUMET.
New basal insulin analogs have improved diabetes management by reducing hypoglycemic episodes and improving blood glucose levels in type 2 diabetes patients. Modern physiological basal insulin replacement has made optimal blood sugar control a realistic target for diabetes management.
Mayo Clinic researchers are developing an artificial pancreas that will deliver insulin automatically and with individualized precision, reducing the need for daily insulin dosing and finger pricks. The system includes a blood sugar monitor, automatic insulin pump, activity monitors, and a central processing unit.
A Mayo Clinic research team has demonstrated a promising alternative strategy for treating type 2 diabetes by blocking the breakdown of insulin. In mouse studies, these mice showed increased insulin levels, weight loss, and improved blood sugar control.
Researchers have found that insulin directly affects the brain's reward circuitry, leading to increased food intake and obesity in mice. This study suggests that insulin resistance may contribute to the difficulty in managing weight loss. Further research is needed to understand the clinical implications of these findings.
Researchers have clarified an important step in the complex control circuit of insulin in the brain. Insulin inhibits nerve impulses, suppressing feelings of satiety and increasing energy expenditure, promoting overweight and obesity.
Researchers at Rensselaer Polytechnic Institute have created a closed-loop artificial pancreas that can automatically monitor blood sugar levels and administer insulin to individuals with Type 1 diabetes. The device aims to reduce the guesswork involved in daily insulin management, which is crucial for maintaining stable glucose levels.
A study of 82 diabetic patients undergoing CABG found aggressive glycemic control did not improve survival rates. Instead, it led to a higher incidence of hypoglycemic events without significant benefits in major adverse effects.
A low-dose insulin treatment has been found to suppress the expression of four precursor proteins involved in Alzheimer's disease pathogenesis. Insulin also showed anti-inflammatory effects on peripheral mononuclear cells, which may lead to a new therapeutic agent for Alzheimer's disease.
Biologists at UC San Diego identified molecular mechanisms in fruit flies that enhance the nervous system's response to smell, potentially regulating human appetite. The discovery could lead to new ways to decrease overeating among obese individuals and increase appetites among the infirm.
Research finds micro-RNAs play a role in type 2 diabetes mechanism, blocking insulin's blood-sugar-reducing effect. Obese mice produce excess miRNA-143, which silences genes responsible for insulin activation.
Researchers at UT Southwestern Medical Center discovered a hormone pathway that could lead to new ways of treating type 1 diabetes independent of insulin. Fibroblast growth factor 19 (FGF19) has insulin-like characteristics and may offer an alternative treatment for diabetes.
A daily pill of pioglitazone prevented type 2 diabetes in more than 70% of participants with obesity and other risk factors. The study also showed a 31% decrease in carotid artery thickening, indicating improved glucose control.
Scientists have identified a protein called Snapin as the molecular switch that controls insulin secretion in pancreatic beta cells. This discovery provides an explanation for the failure of these cells in type 2 diabetes and may lead to new therapies.
Researchers at University of Manchester discover new treatments for congenital hyperinsulinism by correcting gene defects in insulin-producing cells. The breakthrough has the potential to reverse cellular defects and pave way for new drugs, offering real hope for devastating condition.
A new ultra-long-acting form of insulin, degludec, has shown improved glucose control when administered just three times a week, compared to daily injections. This reduces the risk of hypoglycaemia and improves patient adherence.
A recent study published in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that individuals with fatty liver were significantly more likely to develop type 2 diabetes than those without. Fatty liver was shown to be an independent risk factor for type 2 diabetes, regardless of insulin resistance levels.
A new home urine test has been developed to measure insulin production in patients with Type 1 and Type 2 diabetes, replacing multiple blood tests. The test can differentiate between the two types of diabetes and rare genetic forms.
Researchers found that brain insulin suppresses lipolysis, a process breaking down triglycerides and releasing fatty acids, which worsens diabetes. Impaired brain insulin signaling can lead to a vicious cycle of inflammation and insulin resistance.
Researchers found that obesity reduces duration and quality of life by 12 percent, while knee osteoarthritis has a similar impact. A new guideline also recommends targeted prevention and treatment strategies for patients with specific characteristics, such as age, race, and functional status.
UT Southwestern researchers found that eliminating glucagon action can restore glucose tolerance to normal in mice with type 1 diabetes. This suggests a potential 'cure' for the disease, as insulin would no longer be necessary.
A La Jolla Institute team has validated a computer model's ability to predict key information on nasal insulin treatment regimens in type 1 diabetes. The platform accurately predicted biomarker onset and therapeutic outcome, confirming its potential as a valuable research tool.
A new study found that combining exenatide with insulin provides better blood sugar control in patients with type 2 diabetes, achieving near-normal levels in 60% of participants. Additionally, Byetta recipients lost an average of four pounds during the study, while placebo recipients gained two pounds.
Researchers at Joslin Diabetes Center discovered that diabetes can reduce brain cholesterol synthesis, which could impact brain function and increase the risk of Alzheimer's disease. This finding has broad implications for people with diabetes and may also play a role in diabetic neuropathy.
Joslin researchers found that brain cholesterol synthesis decreases in mouse models of diabetes, affecting nerve function and potentially leading to increased appetite and weight gain. The study suggests a link between diabetes and altered brain function, including changes in Alzheimer's disease risk and diabetic neuropathy.
Scientists have identified a crucial protein complex called TORC 2 that plays a significant role in insulin signaling and is linked to both diabetes and cancer. The study found that activating this complex is essential for cells to take up sugar from the blood, and that it may hold potential as a new target for treating type II diabetes.
Researchers have found that beta cells in humans do not replicate after age 30, which could lead to breakthroughs in treating type 1 and 2 diabetes. The discovery uses radioactive carbon-14 dating to determine the number of beta cells remains static after this age.
Two researchers, Dr. Matthew Poy and Dr. James Poulet, have been awarded $1.5 million starting grants from the European Research Council to improve diabetes treatment and understand brain function.
A peer partnership program improved diabetes patients' conditions by reducing blood sugar levels and increasing insulin therapy rates compared to traditional nurse care management. The study found that peer support activated patients to take a more active role in managing their condition.
Researchers have identified a potential target for diabetes drugs by discovering how certain insulin gene mutations cause proinsulin proteins to misfold in pancreatic beta cells. The study found that misfolding of normal proinsulin proteins occurs when mutant protein is present, leading to insulin deficiency and diabetes.
A study found that insulin lowered inflammation and oxidative stress in participants injected with LPS, a common bacteria. Insulin also reduced pro-inflammatory factors and reactive oxygen species generated by the endotoxin.
Researchers at the Buck Institute discovered that insulin signaling affects cell survival and metabolism through translation. The study found that lower insulin signaling is associated with increased tolerance to stress, suggesting a new avenue for disease intervention.
Researchers at NIH used high-resolution microscopy to understand how fat cells absorb glucose in response to insulin. The findings may aid in identifying the interval when someone becomes at risk for developing type 2 diabetes.
A new study reveals that chronically high insulin levels trigger hormonal changes in the pituitary gland, disrupting ovarian function and impairing fertility. Researchers suggest decreasing the pituitary's sensitivity to insulin as a potential target for treatment.
Novo Nordisk's decision to withdraw Mixtard 30 insulin could add £9 million to the NHS drugs bill in England, affecting 90,000 patients with type 1 and 2 diabetes. Alternative biphasic insulins are more expensive and may cause disruption to patient care.
A bioengineered implantable glucose sensor successfully monitored tissue glucose levels in animals for over a year, demonstrating its potential as an alternative to traditional glucose monitoring methods. The device could help people with diabetes adjust their insulin doses and reduce the risk of hypoglycemia.
A study by Johns Hopkins University researchers confirms IGF-1's crucial role in coordinating puberty onset in mice. Administration of IGF-1 to normal female mice triggered pubertal development, highlighting its importance in timely triggering of pulsatile GnRH production.
Research published in Science reveals that muscle weakness and coordination problems in children with neonatal diabetes are caused by neurological issues rather than muscle problems. The study provides implications for developing improved treatments for the disease, which affects one in 100,000 infants in the UK.
A CWRU study of 60 participants with visual impairment and sighted peers found that visually impaired individuals performed slightly better in dosing accuracy, despite using non-visual tools. The results challenge the common warning against visually impaired people using insulin pens.
Researchers found that adding a continuous blood sugar sensor to an insulin pump improved blood sugar control, with significant decreases in A1c levels and no increase in severe hypoglycemia. The study's findings suggest that this technology can help patients of all ages manage their diabetes effectively.
A 26-week randomized study found that once-weekly exenatide significantly improved blood sugar control, inducing a mean weight loss of 2.6kg per patient, compared to insulin glargine's lesser effect and mean weight gain of 1.4kg. The treatment also had lower rates of hypoglycemia and a progressive decrease in bodyweight.
A randomized study found that inhaled insulin plus insulin glargine achieved similar blood sugar control as twice-daily premixed biaspart insulin, with less weight gain and hypoglycemia. The treatment also showed a better safety profile, with fewer cough and lung function issues.